Literature DB >> 34023941

Relevance of chemotherapy and margin status in colorectal liver metastasis.

Wong Hoi She1, Tan To Cheung2, Ka Wing Ma1, Simon H Y Tsang1, Wing Chiu Dai1, Albert C Y Chan1, Chung Mau Lo1.   

Abstract

PURPOSE: This retrospective, single-center study aimed to investigate the importance of chemotherapy and to come up with the optimal liver resection margin length for patients with resectable colorectal liver metastasis (CRLM).
METHODS: Patients who had undergone any form of liver resection for CRLM were reviewed and analyzed. The analyses were broken down into three parts: (1) overall effect of chemotherapy, (2) effect of chemotherapy with positive/negative resection margin, and (3) result of discriminative analysis with optimal margin length analysis.
RESULTS: In total, 381 patients were studied. Among them, 279 received chemotherapy whereas 102 did not. Survival was significantly better in patients with chemotherapy (5-year, 43.6% vs. 25.8%) (p < 0.001). Patients who received chemotherapy (n = 93) with negative margins had better survival than patients (n = 8) with positive margins (5-year, 28.1% vs. 0%) (p = 0.019). On multivariate analysis, margin involvement was the poor prognostic factor for survival. Patients who had chemotherapy (n = 238) with negative margin showed a trend of better survival than patients (n = 41) with positive margins (5-year, 45.7% vs. 29.3%) (p = 0.085). Patients (n = 93) with negative margin and no chemotherapy and patients (n = 41) with positive margin and chemotherapy had comparable survival at 5 years (p = 0.422). On multivariate analysis, tumor number was the prognostic factor for survival. By the discriminant method, 1.09 cm (sensitivity 0.242, specificity 0.718) was determined as the cut-off for optimal margin length. Patients who had margin ≥ 1.09 cm (n = 81) enjoyed significantly better survival (5-year, 54.3% vs. 33.5%) (p = 0.041). On multivariate analysis, margin length ≥ 1.09 cm was the prognostic factor for favorable survival.
CONCLUSION: The results demonstrated the important effect of perioperative chemotherapy and negative margin liver resection in management of patients suffered from CRLM.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chemotherapy; Colorectal liver metastasis; Hepatectomy; Optimal margin

Mesh:

Year:  2021        PMID: 34023941     DOI: 10.1007/s00423-021-02205-w

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  37 in total

Review 1.  Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review.

Authors:  L Spelt; B Andersson; J Nilsson; R Andersson
Journal:  Eur J Surg Oncol       Date:  2011-11-12       Impact factor: 4.424

2.  Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin.

Authors:  K Shirabe; K Takenaka; T Gion; Y Fujiwara; M Shimada; K Yanaga; T Maeda; K Kajiyama; K Sugimachi
Journal:  Br J Surg       Date:  1997-08       Impact factor: 6.939

3.  Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases.

Authors:  L Capussotti; A Muratore; M M Mulas; P Massucco; M Aglietta
Journal:  Br J Surg       Date:  2006-08       Impact factor: 6.939

4.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome.

Authors:  B Cady; R L Jenkins; G D Steele; W D Lewis; M D Stone; W V McDermott; J M Jessup; A Bothe; P Lalor; E J Lovett; P Lavin; D C Linehan
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

5.  Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results.

Authors:  M Minagawa; M Makuuchi; G Torzilli; T Takayama; S Kawasaki; T Kosuge; J Yamamoto; H Imamura
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

6.  Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Authors:  Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

7.  R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?

Authors:  Robbert J de Haas; Dennis A Wicherts; Eduardo Flores; Daniel Azoulay; Denis Castaing; René Adam
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

8.  Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.

Authors:  Tomoyuki Kato; Kenzo Yasui; Takashi Hirai; Yukihide Kanemitsu; Takeo Mori; Kenichi Sugihara; Hidetaka Mochizuki; Junji Yamamoto
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

9.  Resection of liver metastases from colorectal cancer: the real impact of the surgical margin.

Authors:  D Elias; A Cavalcanti; J C Sabourin; N Lassau; J P Pignon; M Ducreux; C Coyle; P Lasser
Journal:  Eur J Surg Oncol       Date:  1998-06       Impact factor: 4.424

10.  Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Authors:  Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.